COMMUNIQUÉS West-GlobeNewswire

Pyxis Oncology to Participate in Upcoming Investor Conferences
13/05/2026
BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management will [...]
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
13/05/2026
AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage : Obesity and type 2 diabetes mellitus (T2DM) rank among the most urgent and costly healthcare problems facing the world today, contributing [...]
Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
13/05/2026
WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF [...]
BrainsWay Reports First Quarter 2026 Financial Results and Operational Highlights
13/05/2026
R evenue grew approximately 35 % y ear- o ver- y ear to $1 5 .5 million for Q1 2026 Net income increased by over 100 % year-over-year to $ 2. 3 million for Q1 2026 Adjusted EBITDA for Q1 of 2026 more than doubled year- [...]
Rectify Pharmaceuticals to Present Preclinical Data on New Dual Targeted ABCB4/BSEP Positive Functional Modulator at EASL 2026
13/05/2026
Data highlight RTY-406's dual ABCB4/BSEP mechanism and marks the first demonstration of proof of mechanism in a non-human primate model that closely mirrors the human hepatobiliary system BOSTON, May 13, 2026 (GLOBE [...]
Sapu Nano Announces First Patient Dosed in Phase 1b Trial of Sapu003, an Intravenous Deciparticle™ Formulation of Everolimus
13/05/2026
First-in-human study evaluates weekly IV Sapu003 in advanced mTOR-sensitive solid tumors, including HR+/HER2- breast cancer, RCC, NETs, TSC-associated tumors, and HCC SAN DIEGO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- [...]
Intelligent Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year
13/05/2026
Razor-razorblade business model accelerates, with Q3 cartridge revenue up 59% year-over-year, representing 66% of quarterly sales Nine-month revenue reaches $3.07 million, up 39% year-over-year, building on record first [...]
Candel Therapeutics to Present at Upcoming Investor Conferences
13/05/2026
NEEDHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve [...]
Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston
13/05/2026
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Antonio F. Santidrian, PhD, Chief Scientific Officer and Head of Technical Operations for Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a [...]
Cannabix Marijuana Breath Test Achieves Major Milestone: Breath Collection Unit Secures UL and CSA Certifications
13/05/2026
VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) is pleased to announce that its portable Breath Collection [...]
Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update
13/05/2026
- Three patients treated with ZEVASKYN ® in Q1 2026 - - QTC network expands to six sites, with two new additions on the East Coast - - In-licensed radically novel engineered T-cell technology with game changing [...]
PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01
13/05/2026
TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) ( “PharmAla” or the “Company” ), a leader in the research, development, and manufacturing of clinical-grade MDMA and [...]
Anaveon Appoints Thomas P. Mathers as Chair of the Board of Directors
13/05/2026
BASEL, Switzerland, May 13, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage biotechnology company pioneering precision biologics to reprogram the immune system for the treatment of autoimmune and inflammatory diseases, [...]
HepaRegeniX to Present Interim Phase 1b Data for Darizmetinib (HRX215) in a Late-Breaking Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2026
13/05/2026
Tuebingen , Germany, May 13 , 202 6 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage biotech company advancing novel therapies for acute and chronic liver diseases, announces that its abstract highlighting clinical [...]
Fangzhou Showcases “AI+H2H” Chronic Disease Service Innovations at the National Intelligent Medicine Conference
13/05/2026
WUHAN, China, May 13, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, participated in the 2026 National Medical Industry [...]
Valneva Reports First Quarter 2026 Financial Results and Provides Corporate Updates
13/05/2026
Total product sales of €30.5 million Cash position of €105.3 million as of end March 2026, excluding proceeds from successful reserved offering completed in April 2026 1 Program launched in April to further reduce [...]
Valneva publie ses résultats financiers audités et consolidés pour le premier trimestre 2026
13/05/2026
Ventes de produits de 30,5 millions d’euros Position de trésorerie de 105,3 millions d’euros à fin mars 2026, hors produit de la levée de fonds réservée réalisée avec succès en avril 2026 1 Lancement, en avril 2026, d’ [...]
IBA lance AdaPTinsight XR, la nouvelle génération d’imagerie CBCT pour la protonthérapie guidée par l’image
13/05/2026
Une solution d’imagerie CBCT pour les systèmes de protonthérapie Proteus ® offrant une visibilité claire qui permet des traitements IGPT en toute confiance Louvain-la-Neuve, Belgique, le 13 mai 2026 – IBA (Ion Beam [...]
Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026
13/05/2026
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced [...]

Pages